We assessed predictors of discontinuation or change of the first regimen of highly active antiretroviral therapy in 465 HIV-infected adults, in the first year. A total of 187 patients modified their regimen: 45 discontinuing and 142 changing because of clinical/virological failure, intolerance/toxicity or non-adherence. Predictors of modification of the regimen were hepatitis virus C seropositivity, liver cirrhosis, higher baseline viral load, sex (women had a lower risk) and calendar year (lower risk for starting in 2000).
Several studies addressing the reasons for the discontinuation or change of the first regimen of highly active antiretroviral therapy (HAART) reported that up to 30–54% of patients stopped or modified their initial HAART regimen over a follow-up lasting from a median of 48 weeks to 3 years [1–9]. Side-effects and toxicity were the most commonly reported reasons [4,7–15], but only a few studies addressed the predictors of modification of the first regimen [1–3,5–7,11], and just one included hepatitis C virus (HCV) serostatus in the analysis . HIV–HCV co-infection increases the risk of hepatotoxicity in patients on antiretroviral drugs [16–20], and patients with hepatitis experience a greater number of adverse events . We investigated the factors associated with the modification of the initial HAART regimen within the first 12 months, in adult patients naive to antiretroviral drugs and starting therapy between November 1996 and December 2000. Our unit is the only HIV centre in our district and patients’ demographic characteristics reflect the HIV epidemic in Italy , where access to treatment has always been free of charge. Out of 551 patients, we excluded 86 (15.6%) for whom clinical and biochemical data were incomplete. Each regimen included three anti-HIV drugs, with two nucleoside reverse transcriptase inhibitors (NRTI) as the backbone, which was associated either with one protease inhibitor (PI) or one non-nucleoside reverse transcriptase inhibitor (NNRTI), or a third NRTI. Modification was categorized as discontinuation (any interruption of HIV regimen for at least one month), or change (any substitution of at least one drug). The reasons for modification were grouped as clinical/virological failure, intolerance/toxicity and non-adherence. Patients had at least a 60-day follow-up, unless the regimen had been modified before that time. Potential factors associated with modification were: age, sex, risk category, AIDS diagnosis, baseline CD4 cell count and plasma viraemia, hepatitis B virus infection and HCV seropositivity (EIA-3 assay; Roche Diagnostics, Monza, Italy), alanine aminotransaminase (ALT) levels, aspartate aminotransaminase levels, platelet and haemoglobin values, NNRTI or PI-based regimens, year of starting HAART, and liver cirrhosis. Transaminase levels were abnormal if 46 IU/ml or greater. Liver cirrhosis included patients with clinical/biochemical or histological evidence of hepatic disease, with at least one episode of liver decompensation before or during the first year of follow-up.
Association with HAART modification was measured through risk ratios (unadjusted and adjusted risk ratios) calculated using a log binomial model. The latter were calculated using a multiple log binomial model obtained after a backward selection (i.e. we excluded at each step the variable with the higher P value from the log-likelihood ratio test; the final model was obtained when only variables with a P value less than 0.2 were included). In this analysis, continuous variables are shown as categorized. However, another analysis in which variables were untransformed provided similar results.
Out of 465 patients, 371 were men (79.8%), 243 (52.2%) were past or active intravenous drug users (IVDU), and the mean age was 36.2 years (SD ± 9.1). Thirty-eight (8.2%) were non-European citizens (mostly Africans). The mean baseline CD4 cell count was 277 cells/mm3 (SD ± 230), and plasma HIV-RNA levels were 4.2 log copies/ml (SD ± 1). A total of 273 subjects (58.7%) had normal baseline ALT levels, 90 (19.3%) had AIDS, 212 (45.6%) were HCV seropositive (74.9 and 11.5% in the ‘IVDU’ and ‘other than IVDU’ categories, respectively), 24 (5.3%) were hepatitis B surface antigen positive, whereas six (1.3%) were HCV–HBV co-infected. Twenty patients (4.3%) had liver cirrhosis (80% HCV seropositive). A total of 88 (18.9%) patients started HAART in 1997, 138 (29.6%) in 1998, 133 (28.6 %) in 1999, and 106 (22.8%) in 2000.
A total of 368 individuals (79.1%) received a PI-based therapy including indinavir (56.2%), nelfinavir (26.6%) and saquinavir hard gel capsules (13.6%), or ritonavir (3.5%). In this group, 13 (3.5%) received a ritonavir-boosted regimen. A total of 86 individuals (18.5%) received NNRTI-based HAART (46 and 40 on efavirenz and nevirapine, respectively), whereas 11 patients (2.3%) received three NRTI. A total of 187 patients (40.2%) modified their HAART regimen within the first year of treatment. Most of them (142, 75.9%) changed their initial treatment, whereas a minority (45, 24.1%) discontinued therapy (28 patients re-started HAART after a mean of 4.8 months, range 1–23). The reasons for modification were: clinical/virological failure (33, 17.6%), intolerance/toxicity (126, 67.3%), and non-adherence (28, 14.9%).
As shown in Table 1, the predictors of modification were: sex (women had a lower risk), baseline viral load (higher risk for greater values), both HCV seropositivity and liver cirrhosis (higher risk), and calendar year (lower risk for patients starting in 2000). No statistical difference was reported according to PI-based or NNRTI-based therapy.
Our study confirms that a large proportion of patients modifies their regimen within the first year, mostly switching as a result of intolerance or toxicity, as reported in other studies [4,7–10]. As far as the predictors, the decreasing rates of therapy modification by calendar year may reflect the longer experience of physicians in prescribing different medications to different patients. Women were less likely to modify their initial regimen (also according to the three main reasons for modification), similar to one other report , but not other studies [2,5]. Some data suggest that women are more likely both to experience adverse events  and to change therapy if on NNRTI , and to have higher rates of NNRTI-related rash . Sex differences may account for differences in tolerance, toxicity and adherence to HIV drugs .
Therapy modification was more frequent in patients with cirrhosis (in which impaired drug metabolism may increase the dose-dependent side-effects), although the risk for such patients is overestimated, as only patients with a clinically overt illness were included in this group. As far as the role of HCV seropositivity is concerned, the interpretation is more complex. Most HCV-infected patients are also viraemic , and even with normal ALT levels, they have some degree of histological damage [26,27]. In addition, a higher degree of fibrosis [28,29] has been reported in co-infected individuals, but why HCV co-infection should lead to the premature modification of HAART is still unclear. Such patients may be less tolerant and less adherent to treatment, leading to early virological failure, and they certainly have a higher risk of hepatic toxicity [17–19], so even the analysis of the specific reasons for modification may be misleading in such a multifaceted picture.
1. van Roon EN, Verzijl JM, Juttman JR, Lenderink AW, Blans MJ, Egberts ACG. Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. J Acquired Immune Defic Syndr Hum Retrovirol 1999; 20:290–294.
2. d'Arminio Monforte A, Cozzi Lepri A, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS 2000; 14:499–507.
3. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Cozzi Lepri A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001; 15:185–194.
4. Le Moing V, Hene G, Leport C, Leweden C, Duran S, Garré M, et al. Impact of discontinuation of initial protease inhibitor therapy on further vitological response in a cohort of human immunodeficiency virus-infected patients. Clin Infect Dis 2002; 34: 239–247
5. Dorrucci M, Pezzotti P, Grisorio B, Minardi C, Muro SM, Vullo V, et al. Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens. AIDS 2001; 15:1733–1736
6. Kirstein L, Anastos K, Cohen M, Greenblatt R, Levine A, Minkoff H, et al. Patterns and predictors of antiretroviral switching among a large cohort of HIV-1 infected women: 1994–1999. In: XIIIth International AIDS Conference. Durban, South Africa, July 2000 [Abstract TuPeC3384].
7. Grant LA, Silverberg MJ, Palacio H, Minkoff H, Anastos K, Young MA, et al. Discontinuation of potent antiretroviral therapy: predictive value of and impact on CD4 cell counts and HIV RNA levels. AIDS 2001; 15:2101–2108.
8. Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, Piersantelli N, Orani A, Petrosillo N, et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) Study. J Infect Dis 2002; 185: 1062–1069.
9. Girard PM, Guiguet M, Bollens D, Goderel I, Meyohas MC, Lecomte I, et al. Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type-1 infected patients on triple-drug regimen. Clin Infect Dis 2000; 31:987–994.
10. Bonfanti P, Valsecchi L, Parazzini F, Carradori S, Pusterla L, Fortuna P, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. J Acquired Immune Defic Syndr Hum Retrovirol 2000; 23:236–245.
11. Hansel A, Bucher HC, Nuesch R, Battegay M. Reasons for discontinuation of first HAART in a cohort of protease inhibitor naïve HIV-infected patients. J Acquired Immune Defic Syndr 2001; 26:191–197.
12. Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358:1322–1327.
13. Bassetti S, Battegay M, Furre H, Rickenbach M, Flepp M, Kaiser L, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? J Acquired Immune Defic Syndr 1999; 21:114–119.
14. Wit FWNM, van Leeuwen R, Weverling GJ, Jurriaans S, Nauta K, Steingrover R, et al. Outcome and predictors of failure of highly active antiretroviral therapy: one year follow up of a cohort of human immunodeficiency virus. J Infect Dis 1999; 179: 790–798.
15. Schrooten W, Wilkins EG, Castro A, Finazzi R, Pelgrom J, Colebunders R. Stopping anti-retrovirals treatmentent. In: XIIIth International AIDS Conference. Durban, South Africa, July 2000 [Abstract WePeB4292].
16. Rodriguez-Rosado R, Garcià-Samaniego J, Soriano V. Hepatotoxicity after interruption of highly active antiretroviral therapy. AIDS 1998; 12:1256.
17. d'Arminio Monforte A, Bugarini R, Pezzotti P, De Luca A, Antinori A, Mussini C, et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquired Immune Defic Syndr 2001; 28:114–123.
18. Sulkowski MS, Thomas DL, Chaisson R, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74–80.
19. Wit FWNM, Weverling GJ, Weel J, Jurriaans S, Lange JMA. Incidence and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186:23–31.
20. Melvin DC, Lee JK, Belsey E, Arnold J, Murphy RL. The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy. AIDS 2000; 14:463–465.
21. Pezzotti P, d'Arminio Monforte A, Bugarini R, Rezza G, Arici C, Angarano G, et al. Antiretroviral therapy in HIV-infected individuals in clinical practice: are the criteria for initiating and choosing the type of drug regimen based only on immunologic and virologic values? Eur J Epidemiol. 2000; 16:919–926.
22. Moore AL, Kirk O, Johnson AM, Katlama C, Blaxhult A, Dietrich M, et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquired Immune Defic Syndr 2003; 32:452–461.
23. Mazhude C, Jones S, Murad S, Taylor C, Easterbrook P. Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. AIDS 2002; 16:1566–1568.
24. Thurman PA, Hompesch BC. Influence of gender on the pharmacokinetics and pharmacodynamics of drugs. Int J Clin Pharmacol Ther 1998; 36:586–590.
25. George SL, Gebhardt J, Klinzman D, Foster MB, Patrick KD, Schmidt WN, et al. Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. J Acquired Immune Defic Syndr 2002; 31:154–162.
26. Jamal MM, Soni A, Quinn PG, Wheeler DE, Arora S, Johnston DE. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States. Hepatology 1999; 30:1307–1311.
27. Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, et al. Clinical, histological, virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26:1393–1398.
28. Puoti M, Bonacini M, Spinetti A, Putzolu V, Govindarajan S, Zaltron S, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and HIV. J Infect Dis 2001; 183:134–137.
29. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients: the Multivirc Group. Hepatology 1999; 30:1054–1048.
© 2004 Lippincott Williams & Wilkins, Inc.